Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges ...

The Securities & Exchange Commission (SEC) has accused Cassava's founder and former chief executive Remi Barbier and former ...

A former Alzheimer's researcher manipulated the results of a Cassava Sciences drug, with the pharmaceutical company and its ...

Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District Court of Texas, claiming that the company misled investors regarding the Phase ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...

Today, Benzinga 's options scanner spotted 15 uncommon options trades for Cassava Sciences. This isn't normal. The overall ...

Cassava Sciences shares fell in premarket trading Friday after regulators said the company, along with two former executives, will pay more than $40 million to settle charges related to misleading ...

These are the most popular stories from the Wall Street Journal. These stories have not been verified and we cannot vouch their accuracy. U.S.

Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the ...

The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug ...

Relatedly, the SEC also charged Hoau-Yan Wang, a Cassava consultant and an associate professor at the City University of New York's Medical School, for manipulating the reported clinical trial results ...